

Marzia Capelletti

List of Publications by Citations

Source: <https://exaly.com/author-pdf/45866/marzia-capelletti-publications-by-citations.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

65
papers

9,754
citations

35
h-index

66
g-index

66
ext. papers

11,181
ext. citations

12
avg, IF

5.04
L-index

#	Paper	IF	Citations
65	Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. <i>Cell</i> , 2012 , 150, 1107-20	20.0	1304
64	Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. <i>Cancer Cell</i> , 2010 , 17, 77-88	24.3	816
63	Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. <i>Journal of Clinical Oncology</i> , 2008 , 26, 1789-96	2.2	784
62	Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. <i>Nature</i> , 2009 , 462, 1070-4	50.4	766
61	Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. <i>Nature Medicine</i> , 2012 , 18, 382-4	50.5	664
60	Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. <i>New England Journal of Medicine</i> , 2010 , 363, 1727-33	59.2	622
59	A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. <i>Cancer Research</i> , 2011 , 71, 6051-60	10.1	468
58	Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer. <i>Nature Medicine</i> , 2013 , 19, 1469-1472	22.5	420
57	Targeting transcriptional addictions in small cell lung cancer with a covalent CDK7 inhibitor. <i>Cancer Cell</i> , 2014 , 26, 909-922	24.3	294
56	The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers. <i>Cancer Research</i> , 2010 , 70, 10038-43	10.1	264
55	EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors. <i>Clinical Cancer Research</i> , 2015 , 21, 3913-23	12.9	256
54	Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy. <i>Journal of Clinical Oncology</i> , 2013 , 31, 2173-81	2.2	214
53	Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors. <i>Cancer Discovery</i> , 2012 , 2, 934-47	4.4	212
52	Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial. <i>Journal of Clinical Oncology</i> , 2012 , 30, 2063-9	2.2	197
51	Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor. <i>Oncogene</i> , 2010 , 29, 2346-56	9.2	185
50	Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013 , 110, 17041-6	11.5	170
49	Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene. <i>Cancer Research</i> , 2010 , 70, 9827-36	10.1	164

48	Resistance to irreversible EGF receptor tyrosine kinase inhibitors through a multistep mechanism involving the IGF1R pathway. <i>Cancer Research</i> , 2013 , 73, 834-43	10.1	153
47	KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS. <i>Cell</i> , 2018 , 172, 857-868.e15	56.2	142
46	Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR-Mutant Lung Cancer. <i>Cancer Discovery</i> , 2015 , 5, 960-971	24.4	142
45	Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014 , 111, E4869-77	11.5	125
44	A functional landscape of resistance to ALK inhibition in lung cancer. <i>Cancer Cell</i> , 2015 , 27, 397-408	24.3	123
43	Improving the yield of circulating tumour cells facilitates molecular characterisation and recognition of discordant HER2 amplification in breast cancer. <i>British Journal of Cancer</i> , 2010 , 102, 1495-502	8.7	118
42	EGFR exon 19 insertions: a new family of sensitizing EGFR mutations in lung adenocarcinoma. <i>Clinical Cancer Research</i> , 2012 , 18, 1790-7	12.9	115
41	BRCA mutations, molecular markers, and clinical variables in early-onset breast cancer: a population-based study. <i>Breast</i> , 2007 , 16, 280-92	3.6	97
40	Intratumoral Heterogeneity in EGFR-Mutant NSCLC Results in Divergent Resistance Mechanisms in Response to EGFR Tyrosine Kinase Inhibition. <i>Cancer Research</i> , 2015 , 75, 4372-83	10.1	83
39	Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors. <i>Cancer Research</i> , 2017 , 77, 2712-2721	10.1	81
38	Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma. <i>Nature Cancer</i> , 2020 , 1, 493-506	15.4	73
37	The Mutational Landscape of Circulating Tumor Cells in Multiple Myeloma. <i>Cell Reports</i> , 2017 , 19, 218-224	6.6	67
36	Identification of recurrent FGFR3-TACC3 fusion oncogenes from lung adenocarcinoma. <i>Clinical Cancer Research</i> , 2014 , 20, 6551-8	12.9	67
35	Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines. <i>Biochemical Pharmacology</i> , 2009 , 78, 460-8	6	61
34	Predictors of gefitinib outcomes in advanced non-small cell lung cancer (NSCLC): study of a comprehensive panel of molecular markers. <i>Lung Cancer</i> , 2010 , 67, 355-60	5.9	59
33	Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung Cancer. <i>Clinical Cancer Research</i> , 2017 , 23, 204-213	12.9	57
32	Clinical and Molecular Characteristics of NF1-Mutant Lung Cancer. <i>Clinical Cancer Research</i> , 2016 , 22, 3148-56	12.9	49
31	Amplification of Wild-type Imparts Resistance to Crizotinib in Exon 14 Mutant Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2018 , 24, 5963-5976	12.9	42

30	Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant. <i>Nature Communications</i> , 2020 , 11, 2996	17.4	34
29	Epidermal growth factor receptor intron-1 polymorphism predicts gefitinib outcome in advanced non-small cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2008 , 3, 1104-11	8.9	29
28	Identification of Oncogenic and Drug-Sensitizing Mutations in the Extracellular Domain of FGFR2. <i>Cancer Research</i> , 2015 , 75, 3139-46	10.1	26
27	Efficacy of a Cancer Vaccine against ALK-Rearranged Lung Tumors. <i>Cancer Immunology Research</i> , 2015 , 3, 1333-1343	12.5	25
26	A pooled exploratory analysis of the effect of tumor size and KRAS mutations on survival benefit from adjuvant platinum-based chemotherapy in node-negative non-small cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2012 , 7, 963-72	8.9	25
25	Inhibition of microRNA-138 enhances bone formation in multiple myeloma bone marrow niche. <i>Leukemia</i> , 2018 , 32, 1739-1750	10.7	22
24	Buccal mucosa cells as in vivo model to evaluate gefitinib activity in patients with advanced non small cell lung cancer. <i>Clinical Cancer Research</i> , 2007 , 13, 6518-26	12.9	20
23	Bortezomib overcomes the negative impact of CXCR4 mutations on survival of Waldenstrom macroglobulinemia patients. <i>Blood</i> , 2018 , 132, 2608-2612	2.2	19
22	A breast cancer patient from Italy with germline mutations in both the BRCA1 and BRCA2 genes. <i>Breast Cancer Research and Treatment</i> , 2005 , 91, 203-5	4.4	18
21	Profiling of circulating exosomal miRNAs in patients with Waldenström Macroglobulinemia. <i>PLoS ONE</i> , 2018 , 13, e0204589	3.7	13
20	Molecular Profile and Clinical Variables in Brca1-Positive Breast Cancers. A Population-Based Study. <i>Tumori</i> , 2005 , 91, 505-512	1.7	11
19	Acute lymphoblastic leukemia as a clonally unrelated second primary malignancy after multiple myeloma. <i>Leukemia</i> , 2019 , 33, 266-270	10.7	8
18	Whole-Exome Sequencing and Targeted Deep Sequencing of cfDNA Enables a Comprehensive Mutational Profiling of Multiple Myeloma. <i>Blood</i> , 2016 , 128, 197-197	2.2	7
17	The Role of Clonal Hematopoiesis of Indeterminate Potential (CHIP) in Multiple Myeloma: Immunomodulator Maintenance Post Autologous Stem Cell Transplant (ASCT) Predicts Better Outcome. <i>Blood</i> , 2018 , 132, 749-749	2.2	6
16	Genomic and pathological heterogeneity in clinically diagnosed small cell lung cancer in never/light smokers identifies therapeutically targetable alterations. <i>Molecular Oncology</i> , 2021 , 15, 27-42	7.9	6
15	Leukemia vaccine overcomes limitations of checkpoint blockade by evoking clonal T cell responses in a murine acute myeloid leukemia model. <i>Haematologica</i> , 2021 , 106, 1330-1342	6.6	4
14	Characterization of GSTM3 polymorphism by real-time polymerase chain reaction with LightCycler. <i>Analytical Biochemistry</i> , 2004 , 330, 175-7	3.1	3
13	CD155-Tigit Pathway Modulation in Dendritic Cell/Acute Myeloid Leukemia Fusion Vaccine Model. <i>Blood</i> , 2019 , 134, 1386-1386	2.2	2

12	Development of Novel Second Generation DC/Tumor Fusion Vaccine in Lymphoma. <i>Blood</i> , 2019 , 134, 392-392	2.2	2
11	Driver Mutation in Waldenstrom's Macroglobulinemia and Their Clonal Heterogeneity during Progression and Relapse. <i>Blood</i> , 2016 , 128, 1092-1092	2.2	2
10	In Vivo Genome-Wide Crispr Library Screen in a Xenograft Mouse Model of Tumor Growth and Metastasis of Multiple Myeloma. <i>Blood</i> , 2016 , 128, 1137-1137	2.2	2
9	Refractory Pleural Small Cell Carcinoma in Never Smoker. A Case Report. <i>Tumori</i> , 2008 , 94, 434-436	1.7	1
8	Single-Cell RNA Sequencing Reveals Compromised Immune Microenvironment in Precursor Stages of Multiple Myeloma. <i>Blood</i> , 2018 , 132, 2603-2603	2.2	1
7	T Cells Educated By DC/AML Fusions in the Context of 4-1BB Costimulation As a Potent Strategy for Adoptive Cellular Therapy. <i>Blood</i> , 2019 , 134, 2673-2673	2.2	1
6	Synergism between CAR-T Cells and a Personalized Tumor Vaccine in Hematological Malignancies. <i>Blood</i> , 2021 , 138, 737-737	2.2	
5	Transcriptome Sequencing Demonstrates Unique Signature Associated with Durable Clinical Response to DC/AML Fusion Vaccine. <i>Blood</i> , 2019 , 134, 3832-3832	2.2	
4	Potent Synergy between Combination of Chimeric Antigen Receptor (CAR) Therapy Targeting CD19 in Conjunction with Dendritic Cell (DC)/Tumor Fusion Vaccine in Hematological Malignancies. <i>Blood</i> , 2019 , 134, 3227-3227	2.2	
3	Whole Exome Sequencing and Targeted Sequencing Reveal the Heterogeneity of Genomic Evolution and Mutational Profile in Smoldering Multiple Myeloma. <i>Blood</i> , 2016 , 128, 237-237	2.2	
2	Microna-138 Regulates Osteogenic Differentiation and Its Inhibition Presents a Novel Therapeutic Line to Prevent Bone Lytic Lesions in Multiple Myeloma. <i>Blood</i> , 2016 , 128, 4483-4483	2.2	
1	Profiling of Circulating Exosomes in Patients with Waldenström Macroglobulinemia. <i>Blood</i> , 2016 , 128, 2940-2940	2.2	